RxDoctor Payments Data

Ford Ben-Okoli, MD

Family Medicine · Texas City, TXNPI 1184144776

Payments from drug & device makers

$1,338in general payments, 2019–2025

Across 33 payments — averaging $40.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$403
  • Novo Nordisk$245
  • Amgen$190
  • AbbVie$165
  • Inspire Medical Systems, Inc.$102
  • Pfizer$85
  • plus $147 from 5 others

What the payments were for

  • Food & beverage$1,338100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,338 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$37,159
Medicare patients
125
Services billed
479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide40$46,248
EliquisApixaban37$41,520
JardianceEmpagliflozin19$24,286
XareltoRivaroxaban21$12,525
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$7,686
Atorvastatin Calcium380$3,252
Pregabalin23$3,246
Albuterol Sulfate HfaAlbuterol Sulfate101$2,614
Gabapentin143$2,607
Omeprazole97$1,695
Levothyroxine Sodium209$1,684
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,547
Amlodipine Besylate262$1,458
Losartan Potassium173$1,414
Metoprolol Succinate98$1,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$403$46,24840 claims
PfizerEliquis$85$41,52037 claims
GSKAnoro Ellipta$39$7,68614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Texas City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →